- Stellar Biotechnologies (NASDAQ:SBOT) and Paris, France-based Neovacs S.A. ink a term sheet to form a joint venture to manufacture conjugated therapeutic vaccines using Stellar's Keyhole Limpet Hemocyanin (KLH). The aim of the venture is to produce Neovacs' Kinoid product candidates, including IFNa-Kinoid and other KLH-based immunotherapies, for third party customers.
- The JV will be 70% owned by Neovacs and 30% owned by Stellar. Additional details or an expected time line are not provided.
Stellar Bio and Neovacs to form JV to make therapeutic vaccines
Recommended For You
More Trending News
About EDSA Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
EDSA | - | - |
Edesa Biotech, Inc. |